IMPORTANCE The effect of polyvascular disease on cardiovascular outcomes in the background of peripheral artery disease (PAD) is unclear.
Introduction
Patients with peripheral artery disease (PAD) are a high-risk population. 1 Peripheral artery disease enhances the risk of major adverse cardiac events (MACEs), defined as cardiovascular death, myocardial infarction (MI), and ischemic stroke. 2 Observational studies report that among patients with PAD, the risk of cardiac events is greatest in those with concomitant coronary artery disease (CAD) and/or cerebrovascular disease (CVD), a condition known as polyvascular disease. 3 In addition to MACEs, patients with PAD are also at risk for major adverse limb events, which include but are not limited to acute limb ischemia (ALI), major amputation, and lower-extremity revascularization. 4 Antithrombotic strategies are considered the cornerstone therapy for preventing cardiovascular events in patients with PAD. 5 To date, studies evaluating the use of intense antithrombotic therapies in patients with PAD have all demonstrated a heightened risk of bleeding with varying degrees of efficacy in reducing both cardiac and limb events. [6] [7] [8] [9] [10] Antithrombotic therapy in patients with PAD can be particularly problematic as the same comorbidities conferring an increased risk for atherothrombosis, such as older age, diabetes, and renal dysfunction, also predispose this population to bleeding. 11, 12 In the Examining Use of Ticagrelor in Peripheral Artery Disease (EUCLID) trial, monotherapy with ticagrelor compared with clopidogrel did not reduce the rates of MACEs in patients with symptomatic PAD. 13, 14 Using the PAD study population from the EUCLID trial, the present study aims to evaluate the association between polyvascular disease and MACEs as well as major adverse limb events and determine the risk of bleeding associated with polyvascular disease.
Methods

Study Population
This is a post hoc secondary analysis of the EUCLID trial (ClinicalTrials.gov identifier: NCT01732822).
The study design and results of the EUCLID trial have been previously published. 13, 14 Briefly, EUCLID was a double-blind, active-comparator trial of ticagrelor vs clopidogrel in patients with symptomatic PAD.
Between December 31, 2012, and March 7, 2014 , patients with symptomatic PAD were randomized in a 1:1 double-blind manner via an interactive voice-or web-response system to receive ticagrelor, 90 mg twice daily, or clopidogrel, 75 mg once daily. Patients were followed up until May 9, 2016. On screening, patients were eligible if they were aged 50 years or older and had symptomatic PAD, defined as an ankle-brachial index of 0.80 or less or lower-extremity revascularization more than 30 days before randomization. With regard to ankle-brachial index eligibility criteria, a confirmation measurement of 0.85 or less was also required at the time of randomization. In settings in which the ankle-brachial index was 1.40 or greater at screening, a toe-brachial index cutoff level of 0.60 or lower was implemented, 2C19 allele variants; (3) need for long-term anticoagulation; and (4) elevated bleeding risk. In the present study, patients were grouped according to baseline history of CAD or CVD in the following manner: PAD alone, PAD + CAD, PAD + CVD, and PAD + CAD + CVD. History of CAD or CVD was based on clinical data obtained at the start of the trial. Prior CAD was defined on the case report form as a history of percutaneous coronary intervention, coronary artery bypass grafting, or MI. Prior CVD was defined based on the case report form as a history of stroke or transient ischemic attack, carotid stenosis, or carotid revascularization.
All patients provided written informed consent, and the trial protocol was reviewed and approved by appropriate ethics committees at participating sites. The EUCLID publication committee approved the post hoc analysis with waiver of informed consent.
End Points
The primary end point in the EUCLID trial was a composite of cardiovascular death, MI, or ischemic stroke. For the present study, key secondary end points included the individual components of the primary end point and ALI leading to hospitalization, major amputation, and lower-extremity revascularization. The primary end point of Thrombolysis in Myocardial Infarction (TIMI) major bleeding was also evaluated.
Statistical Analysis
The present analysis was conducted from June 1, 2017, to February 5, 2018 . Continuous variables are presented as medians with interquartile ranges and were assessed using the Kruskal-Wallis test.
Categorical variables are reported as counts and percentages and were assessed using χ 2 tests. End points were assessed according to the following groups: PAD alone (reference group), PAD + CAD, PAD + CVD, and PAD + CAD + CVD. Analyses were performed according to the intention-to-treat principle and included all randomized patients. The interaction between the number of diseased vascular beds and treatment cohorts-ticagrelor or clopidogrel-for the primary end points was assessed. A Cox proportional hazards regression model was applied to determine the association between polyvascular disease and outcomes. Results of the models include adjusted hazard ratios (aHRs), 95% CIs, and P values.
Adjustment variables for each outcome were chosen using a stepwise selection process with α met inclusion criteria owing to a history of lower-extremity revascularization.
Compared with patients with PAD alone, those with polyvascular disease were older; more likely to have multiple comorbidities, such as diabetes, hypertension, or hyperlipidemia; and more likely to have undergone prior lower-extremity revascularization ( Table 1) .
Before randomization, patients with polyvascular disease were more frequently treated with aspirin, clopidogrel, dual antiplatelet therapy, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers. In contrast, patients with PAD alone were more frequently treated with cilostazol (Table 1) .
Outcomes
The rate of the primary end point of the composite of cardiovascular death, MI, or ischemic stroke, defined as events per 100 patient-years, was greatest in patients with polyvascular disease, with the lowest event rates occurring in patients with PAD alone (3.4), followed by PAD + CVD (4.8), PAD + CAD (5.7), and PAD + CAD + CVD (8.1) (log-rank P < .001) ( Table 2 and Figure 1A ). Rates for the individual components of cardiovascular death and MI increased in a similar incremental fashion with each additional diseased vascular bed. Rates for ischemic stroke were heightened only among patients with CVD-those with PAD + CVD or PAD + CAD + CVD. Figure 1B , C, and D depict the 36-month Kaplan-Meier rates for the individual components of the primary composite end point (cardiovascular death, MI, and ischemic stroke, respectively) according to vascular disease phenotype. There was no significant difference in rates of ALI requiring hospitalization and major amputation among patients with polyvascular disease compared with patients with PAD alone.
The rate of lower-extremity revascularization increased per 100 patient-years with each additional diseased vascular bed, with the lowest rates in patients with PAD alone (4.8), followed by PAD + CVD (5.9), PAD + CAD (6.0), and PAD + CAD + CVD (7.6) (log-rank P < .001). The rate of TIMI major bleeding, defined as events per 100 patient-years, was similar among all 4 cohorts: PAD alone (0.70); PAD + CVD (0.76); PAD + CAD (0.84); and PAD + CAD + CVD (0.89) (log-rank P = .58) ( Table 2 ). The ticagrelor vs clopidogrel comparison among all of the polyvascular disease subgroups (PAD + CAD, PAD + CVD, and PAD + CAD + CVD) did not demonstrate an interaction P value of significance for the primary end points of cardiovascular death, MI, or ischemic stroke (P = .71), and major bleeding (P = .31).
Compared with patients with PAD alone and following adjustment for baseline variables, a stepwise increase in risk of the primary end point was observed with each additional diseased 
Discussion
In this study of 13 885 patients with PAD after adjustment for significant baseline variables, polyvascular disease (>1 diseased vascular bed at baseline) was associated with an increased risk of MACEs, defined as cardiovascular death, MI, or stroke, in patients in whom the reference is established isolated PAD. The risk of ALI requiring hospitalization and major amputation was similar in patients with PAD with polyvascular disease compared with patients with PAD alone. The risk of lower-extremity revascularization, however, was increased among patients with polyvascular disease. The risk of the primary safety end point of TIMI major bleeding after adjustment was similar in patients with polyvascular disease compared with those with PAD alone. These findings have both mechanistically and clinically important implications.
To our knowledge, the effect of polyvascular disease on both major adverse cardiac and limb events has not been previously evaluated in a contemporary clinical trial of patients with symptomatic PAD. Previous studies involving a large international registry of patients with stable atherosclerotic disease (CAD, CVD, or PAD) have found the existence of polyvascular disease to confer a heightened risk of ischemic events. 3, 15 Consistent with these findings, patients with PAD and a Event rates defined as number of events per 100 patient-years of follow-up.
b P values are from the log-rank test comparing the Kaplan-Meier rates across groups. polyvascular disease from the EUCLID trial demonstrated an incremental rise in MACE risk with each additional diseased vascular territory. The risk of the individual components of cardiovascular death and MI also rose in a stepwise fashion with each additional diseased vascular territory. The novelty of the present analysis is the finding that polyvascular disease is independently associated with an increase in lower-extremity revascularization. In addition, among the EUCLID trial population, geographic location has been demonstrated to also affect the rate of lower-extremity revascularization. 16 In light of an observed increased risk of adverse events associated with polyvascular disease, one would expect to detect a greater clinical benefit among these subpopulations owing to a greater opportunity for treatment benefit; however, this outcome was not the case in the present study. The interpretation for this difference likely stems from the overall findings of the EUCLID trial, which were neutral. Close examination of these previously published results demonstrates event rates and times-to-event analyses for efficacy and safety end points to be similar among both ticagrelor and clopidogrel cohorts. Second, among patients with polyvascular disease, the increase in ischemic events is related to the polyvascular disease phenotype. For example, patients with PAD + CAD experienced the highest rates of cardiovascular death and MI, while patients with PAD + CVD experienced the highest rates of ischemic stroke. The addition of CAD or CVD was not associated with a higher risk of the adverse limb events of ALI or major amputation; however, CAD and CVD were linked to a heightened risk of lower-extremity revascularization. These data highlight the increased risk of CAD and CVD among patients with PAD and the need to identify potent preventive antithrombotic therapies.
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In addition, we evaluated the risk of major bleeding in patients with polyvascular disease on a background of PAD. Evaluation of a large registry of patients presenting with acute coronary syndromes found polyvascular disease to be associated with increased rates of blood transfusion among patients who did not undergo coronary artery bypass grafting. 2 In our analysis, there was no clear evidence that polyvascular disease conferred an increased risk of major bleeding among patients with PAD.
Limitations
The present study has limitations. First, it is a post hoc secondary analysis of subgroups of the overall EUCLID trial; as such, results are considered hypothesis generating, and caution should be used when interpreting all findings. Second, the median follow-up period was 36 months; therefore, any potential benefit or risk of ticagrelor therapy in a stable outpatient PAD population beyond this time frame is uncertain.
Conclusions
In EUCLID, a randomized trial of ticagrelor vs clopidogrel in patients with symptomatic PAD, polyvascular disease was present in 43.8% of the study population. Compared with patients with PAD alone, the risk of MACEs and lower-extremity revascularization increased with atherosclerosis across multiple vascular territories. Polyvascular disease, however, was not associated with an increased risk of TIMI major bleeding compared with patients with PAD alone. These data highlight the increased risk of CAD and CVD among patients with PAD and the need to identify potent preventive antithrombotic therapies.
